{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"NIcht-interventionelle Unbedenklichkeitsstudie zur Vertr&#228;glichkeit und Sicherheit von <b>Octagam 5% und Octagam 10%</b>.","eudractNumber":null,"id":2824,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T12:19:18+02:00","shortTitle":"GAM-33 Octagam","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":11341,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-01-28T09:00:35+01:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":6546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-04-01T11:55:14+02:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Long-Term Follow up Protocol for subjects treated with gene-modified T Cells<br />","eudractNumber":"2017-001465-24","id":5382,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03435796","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2019-01-10T13:02:46+01:00","shortTitle":"GC-LTFU-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11855,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-10T08:43:49+01:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"German Lymphoma Alliance-Registry","eudractNumber":null,"id":11945,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-01T10:52:18+02:00","shortTitle":"GLA-Registry","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen und verwandter Erkrankungen in Verbindung mit einer prospektiven Biomaterialsammlung","eudractNumber":null,"id":1513,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[],"nctNumber":"NCT02872987","phase":null,"recruitmentStart":"2009-09-15T08:32:21+02:00","shortTitle":"GMALL Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Eine offene, forschungsinitiierte Phase I/II &#8211; Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refrakt&#228;rer ALL","eudractNumber":"2021-001384-25","id":9997,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05182385","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-02-14T11:58:28+01:00","shortTitle":"GMALL-BLIVEN","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)","eudractNumber":"2022-000760-21","id":7902,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-07-13T12:23:49+02:00","shortTitle":"GMALL-EVOLVE","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label<br /><div><br /></div><div>DRKS00033264</div>","eudractNumber":null,"id":9047,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-05-16T13:07:02+02:00","shortTitle":"HARBOUR","therapeutical":false,"therapyLines":[]}]}